Home  >  TopNews
TopNews
+ Font Resize -

Pharma industry in south has great potential in production of drugs for chronic diseases: S V Veeramani

Our Bureau, Chennai
Saturday, July 15, 2017, 08:00 Hrs  [IST]

The potential of south Indian pharma industry in production of drugs for chronic diseases is high and it is growing steadily compared to such in other parts of the country.

Diabetes, cancer, liver diseases and infertility are the four major therapy segments that the pharmaceutical companies in south can focus. As far as Tamil Nadu is concerned, it is becoming a region with large number of diabetic patients. The manufacturers should consider this trend for good business prospects, according to S V Veeramani, immediate past national president of the Indian Drugs Manufacturers Association (IDMA).

All the south Indian manufacturers, especially those from Tamil Nadu, have the potential to manufacture as many drugs as required for the entire south India. Concentration on therapies for chronic diseases can uplift the units from their present pitiable situation. The state has a good quality culture and all the products manufactured here are better in quality. Compared to other parts of the country, the percentage of NSQs is very less in Tamil Nadu, he pointed out.

According to Veeramani, a major share of the formulations marketed for domestic sales is from the six south Indian states like Telengana, Andhra Pradesh, Tamil Nadu, Pondicherry and Karnataka. IDMA’s analysis report reveals a figure of 30% contribution of the total production in the country is from southern states, he said. This share can be increased to higher levels provided the manufacturers focus on drugs for chronic diseases.

“There are certain key characteristics for the Tamil Nadu pharma industry which distinguish it from other states. When the percentage of NSQ drugs all over India is 3 – 4 percent, in Tamil Nadu it is less than 3%. And the industry from south India contributes 30% for the domestic sales and 40% for exports. The only thing required for the growth of pharma sector is to upgrade the facilities of the plants. Currently, our country is exporting drugs to 220 countries. Similarly the marketers should also concentrate on chronic diseases,” Veeramani said.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :   
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |